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Introduction: Use of hydroxyethyl starch (HES) in septic patients is reported to increase the mortality and incidence
of renal replacement therapy (RRT). However, whether or not use of HES would induce the same result in non-septic
patients in the intensive care unit (ICU) remains unclear. The objective of this meta-analysis was to evaluate 6% HES
versus other fluids for non-septic ICU patients.
Methods: Randomized controlled trials (RCTs) were searched from Pubmed, OvidSP, Embase database and Cochrane
Library, published before November, 2013. A meta-analysis was made on the effect of 6% HES versus other fluids for
non-septic ICU patients, including mortality, RRT incidence, bleeding volume, red blood cell (RBC) transfusion and fluid
application for non-septic patients in ICU.
Results: Twenty-two RCTs were included, involving 6,064 non-septic ICU patients. Compared with the other fluids,
6% HES was not associated with decreased overall mortality (RR = 1.03, 95%CI: 0.09 to 1.17; P = 0.67; I2 = 0). There was
no significant difference in RRT incidence, bleeding volume and red blood cell transfusion between 6% HES group
and the other fluid groups. However, patients in HES group received less total intravenous fluids than those receiving
crystalloids during the first day in ICU (SMD= −0.84; 95%CI: −1.39 to −0.30; P = 0.003, I2 = 74%).
Conclusions: This meta-analysis found no increased mortality, RRT incidence, bleeding volumes or RBC transfusion in
non-septic ICU patients, but the sample sizes were small and the studies generally were of poor quality.Introduction
Since the 1970s, hydroxyethyl starch (HES) has been widely
used for volume expansion therapy. A cross-sectional study
reported that about 37.1% patients in the ICU received
daily plasma volume expansion, mostly using HES [1].
Another study showed that rapid intravenous infusion
of HES increases cardiac output and expands blood
volume more effectively than crystalloids [2]. Numerous
reviews without meta-analyses also support the clinical
application of HES [3,4].* Correspondence: docwangyw@sina.com; pfdbsxubin@163.com
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unless otherwise stated.However, the safety of HES for plasma volume expansion
is still under research, especially as many studies by Boldt
have been retracted due to scientific misconduct. Recently,
three large-sample randomized controlled trials (RCTs)
[5-7] and meta-analyses [8-10] have indicated that HES
increases the need for renal replacement therapy (RRT) in
critically ill patients and mortality in sepsis patients. The
statement issued by the European Society of Intensive Care
Medicine (ESICM) recommends that products containing
HES should not be used in septic patients (1B), other
intensive care patients at a high risk of acute kidney injury
(AKI) (1C) or patients with head injury or intracranial
bleeding (1C) [11]. However, another international
multi-center large-sample RCT reported the use of
colloids (including HES, gelatin, dextran and albumin)
versus any crystalloids for volume expansion therapy to
decrease 90-day mortality without increasing the need for
in ICU patients [12]. Hence, we wanted to further study
the effect of the use of HES in ICU patients.is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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who require volume expansion therapy, such as those
with acute hypovolemia arising from trauma, bleeding
or surgery. So far, there is a lack of effective and
comprehensive evidence-based trials focusing on the
safety of HES for non-septic patients in the ICU.
However, Zarychanski et al. [8] have reported on the
use of HES in critically ill patients, and performed
subgroup analyses to compare trials of septic versus
non-septic patients in their meta-analysis, the results
were inconsistent between subgroups. After exclusion
of the Boldt’ papers HES was shown to significantly
increase the risk of mortality in all critically ill patients.
However, HES did not increase the mortality in the
non-septic subgroup, which was contradictory to the
result obtained from the septic subgroup in their
paper. Furthermore, subgroup analysis was performed
only for mortality; AKI and RRT incidence were not
reported in the non-septic subgroup. Mutter et al. [9]
made a systematic review to assess the effects of HES
versus other fluids on kidney function in all patient
populations. HES products were found to increase the
risk in AKI and RRT in all patients. Surprisingly,
Mutter et al. detected a significant decrease in risk and
injury of renal function according to the risk, injury,
failure, loss of kidney function and end-stage kidney
disease (RIFLE) criteria in the non-septic subgroup
treated with HES versus other fluids [9].
Two meta-analyses published recently demonstrated
that use of HES for volume expansion therapy during
surgery was not associated with increased postoperative
mortality or RRT use [13,14], which differed from
the studies focusing on septic patients. However,
Cittanova et al. reported that HES significantly increases
serum creatinine concentrations during the first 8 days
after transplantation in kidney-transplant recipients [15].
These results suggest that HES could have different effects
on different diseases. Therefore, whether or not use of
HES in non-septic ICU patients could induce a result
similar to that seen in septic ICU patients needs to
be further confirmed. The aim of the present study
was to evaluate the impact of 6% HES on mortality,
RRT use, bleeding volume, red blood cell (RBC)
transfusion and fluid application among non-septic
patients in the ICU.
Materials and methods
According to the methodology recommended by the
Cochrane Collaboration [16], we included related
RCTs for analyzing the safety of 6% HES for non-
septic patients in the ICU. The primary endpoints
were overall mortality and use of RRT, and the secondary
endpoints were bleeding volume, RBC transfusion and
fluid application. We reported the meta-analysis accordingto the preferred reporting items for systematic reviews
and meta-analyses (PRISMA) criteria [17].
Studies were selected if they met the following criteria:
1) RCTs; 2) patient age ≥18 years; 3) studies consisting
of a group of patients in whom 6% HES was used, and a
control group receiving other intravenous fluids in the
ICU; and 4) subgroups of non-septic patients who were
reported to have received 6% HES and other intravenous
fluids in the ICU. Studies were excluded if they had any
of the following characteristics: 1) septic patients as
research subjects; 2) no group receiving 6% HES; 3)
no data available and 4) Boldt’s research studies.
Search strategy
We searched Pubmed, OvidSP, Embase database and the
Cochrane Library, including reference lists of relevant
clinical trials, systematic reviews and meta-analyses
published before November 2013, and that met the
above criteria. The term in MeSH was “Hetastarch”
and related free words were also searched such as
“hydroxyethylstarch”, “HES”, “Tetraspan”, “Voluven” and so
on. The search was limited by “RCTs”, “human” and “adult”.
“Language” was not a restricted searching condition. Details
are provided in Additional file 1.
Data extraction
Two reviewers (BH, BX) independently screened the
results of the retrieved and acquired full texts that
met the above criteria. For each acquired article, the
two reviewers independently extracted the valid data,
including overall mortality, RRT use, bleeding volume,
RBC transfusion, and fluid application during the first
day in ICU. A third reviewer (XX) would arbitrate in the
event of any disagreement between the two reviewers.
Risk of bias assessment and study quality
The Cochrane Collaboration risk-of-bias tool [16] was
used to evaluate the internal validity of the included articles.
The tool contained the following items: generation of
random sequence, allocation concealment, blinding, incom-
plete data reporting, selective reporting results and other
problems that could put the study at a risk of bias. Quality
assessment was evaluated using mthe odified Jadad
score [18]. The scale is a score from 0 to 7 (highest
level of quality) according to generation of random se-
quence, allocation concealment, blinding, and withdrawals
of clinical trials. High quality was defined by a Jadad score
of 4 to 7; low quality was defined by a Jadad score ≤3.
Statistical analysis
Review Manager (RevMan, version 5.2) was used to
analyze the included studies and data. Standard mean
difference (SMD) was used for pooling continuous data.
When median and extreme values were presented in the
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and SD according to relevant formulas [19]. If median
and quartile range were reported, mean value and SD
were estimated by the method provided in the 7.7.3.5
section of the Cochrane Handbook [16]. If the HES
groups or control groups included more than one group,
the respective data were pooled (weighted estimate)
according to the Cochrane Handbook (7.7.3.8 section)
[16]. For non-continuous data, relative risk (RR) was
adopted. Heterogeneity was quantified using the I2-test
[20]. The fixed effects model was selected if there was no
heterogeneity (I2 < 50%), and the random effects model
was selected in the event of 50% ≤ I2 < 75%. A sensitivity
analysis or subgroup analysis was performed to exclude
the heterogeneity if I2 was ≥75%, otherwise meta-analysis
was not carried out. Publication bias was tested using
funnel plots and the Egger’s test [21]. Two-sided tests
were performed with a significant difference at P <0.05.
Results
RCTs included
The flow diagram of this meta-analysis is presented in
Figure 1. A total of 2,919 articles were retrieved, of
which 2,897 were excluded. Finally, 22 eligible RCTs
were included in this meta-analysis according to the
inclusion and exclusion criteria.Figure 1 Flow diagram of this meta-analysis.Characteristics of the included studies and study quality
The characteristics of the 22 included RCTs are shown
in Table 1. Of these, 14 RCTs reported patients who had
undergone complex surgical procedures needing volume
expansion therapy in the ICU [22-35], and 8 RCTs
reported patients with other diseases (such as car-
diac arrest, trauma, and so on) who received volume
expansion therapy in the ICU [6,36-42]. Two RCTs
reported data for a non-septic subgroup [6,38], and
we included these data. These studies used different
indicators to evaluate whether patients reached
circulation stabilization. For example, one study used
cardiac index [22], some chose urine and central venous
pressure [37,41,42], and others combined several indicators
[23,24,28-32,39].
Among our included articles, 14 RCTs [6,23-27,32,34,
36,38-42] reported the overall mortality; 9 RCTs
[24-27,31,34,37,41,42] reported the incidence of RRT;
10 RCTs [22-24,27-31,33,35] reported bleeding volume
after surgery; 10 RCTs [22,24-28,30,31,33,35] reported
RBC transfusion after surgery; and 9 RCTs [23,27-30,
32,33,37,42] reported fluid application during the first
day in ICU (Additional file 2: Table S1). According to
the modified Jadad score, high quality was determined
in 13 studies, and low quality was determined in 9
studies (Table 2).
Table 1 Characteristics of articles included, patient diagnosis, number of participants, interventions, and related details of reports
Author, year Diagnosis Patients
(n)







CAStudy fluids n1 Control fluids n2
Ley, 1990 [22] After cardiac surgery 21 6% HES 450/0.7 11 Normal saline 10 Up to 1.5 L CI >2.0 L/min/m2 NS PD
Beards,1994 [36] Hypovolemia 25 6% HES 450/0.7 13 Gelatin 12 500 mL bolus NS 15 to 30 minutes PD
Van der Linden, 2005 [23] After cardiac surgery 132 6% HES 130/0.4 64 Gelatin 68 Maximum
50 mL/kg/day
PAOP, 8 to 15 mmHg NS PD
CI >2.5 L/min/m2
Urine >0.5 mL/kg/h
Chen, 2006 [37] Burn 66 6% HES 130/0.4 33 Plasma 33 2328 ± 271 mL CVP 7 to 14 mmHg 48 h CA
Urine >0.5 mL/kg/h
Mahmood, 2007 [24] After aortic aneurysm
surgery
62 6% HES 130/0.4 21 Gelatin 20 Surgery, 3 ml/kg/h MAP >85 mmHg Surgery and ICU PD
6% HES 200/0.62 21 CU, as needed CVP 8 to 10 mmHg
Godet, 2008 [25] After abdominal
aortic surgery
65 6% HES 130/0.4 32 Gelatin 33 As needed Doctor’s judgement Surgery and
6 d in ICU
PD
Mukhtar, 2009 [26] After transplantation
surgery
40 6% HES 130/0.4 20 Albumin 20 Maximum
50 mL/kg/day
CVP, 5 to 7 mmHg Surgery and
4 d in ICU
PD
Ooi, 2009 [27] After cardiac surgery 90 6% HES 130/0.4 45 Gelatin 45 As needed CVP, 10 to 14 mmHg NS PD
Schramko, 2009 [28] After cardiac surgery 45 6% HES 130/0.4 15 Albumin 15 NS PAWP, 10 to 14 mmHg NS PD
6% HES 200/0.62 15 CI >2.0 L/min/m2
Choi, 2010 [29] After abdominal
aortic surgery
36 6% HES 130/0.4 18 Albumin 18 Maximum
20 mL/kg in ICU
PAOP, 10 to 14 mmHg NS PD
CI >2.0 L/min/m2
Urine >0.5 mL/kg/h
Gondos, 2010 [38] Hypovolemia 106 6% HES 130/0.4 26 RL 28 10 mL/kg NS NS PD
Gelatin 25
Albumin 27
Heradstveit, 2010 [39] After cardiac arrest 19 6% HES 200/0.5 10 RL 9 maximum
500 mL/24 h
MAP >60 mmHg Observation
period
PD
HR, 60 to 100/min
CVP, 8 to 12 mmHg
Inal, 2010 [40] Hypovolemia 30 6% HES 130/0.4 15 Gelatin 15 500 mL NS NS PD
Schramko, 2010 [30] After cardiac surgery 45 6% HES 130/0.4 15 RL 15 28 mL/kg PCWP, 10 to15 mmHg 16 to 20 h in ICU PD
Gelatin 15 CI > 2.0 L/min/m2
Du, 2011 [41] Acute pancreatitis 41 6% HES 130/0.4 20 RL 21 as needed CVP, 8 to 15 mmHg 8 d in hospital CA
1:3 with saline Urine >0.5 mL/kg/h
SBP >90 mmHg










Table 1 Characteristics of articles included, patient diagnosis, number of participants, interventions, and related details of reports (Continued)
Urine >0.5 mL/kg/h
Lee, 2011 [31] After cardiac surgery 106 6% HES 130/0.4 53 Crystalloid 53 Maximum 50 mL/kg/d CI >2.2 L/min/m2 NS PD
SvO2 > 60%
Urine >0.5 mL/kg/h
Yang, 2011 [32] After hepatectomy 81 6% HES 130/0.4 26 RL 25 1,000 mL/d*3d CVP, 5 to 9 mmHg 5 d CA
Albumin 30 500 mL/d*2d MAP, 60 to 80 mmHg
Myburgh, 2012 [6] Non-septic patients 4720 6% HES 130/0.4 2337 Normal saline 2383 500 mL bolus,
maximum 50 mL/kg/d
NS 90 d CA
Alavi, 2012 [33] After cardiac surgery 92 6% HES 130/0.4 32 RL 29 As needed CVP, 7 to 14 mmHg Surgery and ICU PD
Gelatin 31
Nagpal D, 2012 [34] After cardiac surgery 70 6% HES 130/0.4 35 Crystalloid 35 1 to 3.0 L/d NS NS PD
Kimenai, 2013 [35] After cardiac surgery 60 6% HES 130/0.4 30 Gelatin 30 NS NS NS PD
RL, Ringer lactate; n, number of overall patients; n1, number of patients in intervention group; n2 number of patients in control group; NS, not stated; CI, cardiac index; PAOP, pulmonary artery occlusive pressure; CVP,
central venous pressure; MAP, mean arterial pressure; PAWP, pulmonary artery wedge pressure; HR, heart rate; PCWP, pulmonary capillary wedge pressure; SBP systolic blood pressure; SvO2, mixed venous oxygen
























Van der Linden, 2005 [23] Low Unclear High Low Low Low 4
Mahmood, 2007 [24] Low Low High Low Low Low 5
Godet, 2008 [25] Low Low High Low Low High 4
Mukhtar, 2009 [26] Unclear Low Unclear Low Low Unclear 4
Schramko, 2009 [28] Unclear Low Unclear Low Low Low 4
Gondos, 2010 [38] Unclear Low Unclear Low Low Low 4
Schramko, 2010 [30] Unclear Low High Low Low Low 4
Du, 2011 [41] Low Unclear Unclear High High Low 4
James, 2011 [42] Low Low Low High Low Low 6
Myburgh, 2012 [6] Low Low Low Low Low Low 7
Alavi, 2012 [33] Unclear Low Low Low Low Low 4
Nagpal, 2012 [34] Low Low Low Unclear Low Low 5
Kimenai, 2013 [35] Low Unclear High Low Low Low 4
Low Quality
Ley, 1990 [22] Unclear Unclear Unclear Low Low Unclear 2
Berard, 1994 [36] Unclear Unclear Unclear Low Low Low 2
Chen, 2006 [37] Low Unclear High Low Low Unclear 3
Ooi, 2009 [27] Unclear Unclear High Low Unclear Low 2
Choi, 2010 [29] Low Unclear Unclear Low Low Low 3
Heradstveit, 2010 [39] Unclear Unclear High Low Low High 2
Inal, 2010 [40] Unclear Unclear Unclear Low Unclear Low 2
Lee, 2011 [31] Unclear Unclear High Low Low Low 2
Yang, 2011 [32] Low Unclear Unclear High Low Low 3
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A total of 14 articles reported the overall mortality,
involving 5,593 patients. Compared with the other types
of fluids (crystalloids, gelatine or albumin), the use of 6%
HES was not associated with decreased overall mortality
(RR = 1.03, 95% CI 0.90 to 1.17; P = 0.67; I2 = 0)Figure 2 Forest plot of pooled risk ratio for overall mortality. HES, hyd(Figure 2). Publication bias was not found by the Egger’s
test (P = 0.85) or funnel plots (Figure 3).
Renal replacement therapy
Nine articles reported the incidence of RRT, showing
that 6% HES did not increase RRT use as compared withroxethyl starch. M-H, Mantel-Haenszel.
Figure 3 Funnel plot of overall mortality. RR, relative risk. SE, standard error.
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I2 = 0%) (Figure 4). Funnel plots showed no publication
bias (Figure 5), and the P-value from Egger’s test was 0.58.
Bleeding volume and RBC transfusion
Bleeding volume was reported in 10 articles. Of these,
we only pooled seven articles [22,27,28,30,31,33,35] in
this meta-analysis, which all reported bleeding volume
after surgery. Three articles [23,24,29] were excluded, as
bleeding volume was reported from surgery or during
several periods after surgery. Data from Schramko et al.,
Alavi et al. and Kimenai et al. were converted into mean
and SD according to the method above [16,19]. There
was no significant difference in bleeding volume between
the 6% HES group and other fluid groups (SMD = −0.10,
95% CI −0.29 to 0.08; P = 0.28; I2 = 0%) (Figure 6A). Egger’s
test showed no publication bias (P = 0.35).
Nine articles reported RBC transfusion, and five
articles [22,23,26,31,42] reporting RBC transfusion
after surgery were included and showed no significant
difference between the HES group and other fluids groupFigure 4 Forest plot of pooled risk ratio for use of renal replacement(SMD= −0.13; 95% CI −0.33 to 0.08; P = 0.23; I2 = 4%)
(Figure 6B). Egger’s test showed no publication bias
(P = 0.51). Four articles were excluded because two of
them [28,33] only reported overall volume of RBC
transfusion, and the other two [24,26] reported RBC
transfusion before surgery. Data from three articles
were transformed [23,26,42].
Fluid application
Fluid application during the first day in ICU was reported
in nine articles, but there was significant data heterogeneity
(I2 = 94%). Knowing that colloids and crystalloids have
different effects on volume expansion, a subgroup analysis
was performed by the type of fluid used. Patients receiving
6% HES needed fewer total intravenous fluids than those
receiving crystalloids (SMD=−0.84, 95% CI −1.39 to −0.30;
P = 0.003; I2 = 74%) (Figure 7A). There was no significant
difference between the 6% HES group and albumin group
(SMD = 0.26, 95% CI −0.17 to 0.70; P = 0.23; I2 = 13%)
(Figure 7C). In this subgroup, data from Choi et al. [29]
were excluded, because they were reported in severaltherapy. HES, hydroxethyl starch. M-H, Mantel-Haenszel.
Figure 5 Funnel plot of incidence for renal replacement therapy. RR, relative risk. SE, standard error.
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the data from the authors. Although subgroup analysis
was carried out, there remained great heterogeneity in the
fluid application between the HES group and the gelatin
group. A sensitivity analysis identified that the trial from
Alavi et al. [33] was responsible for the heterogeneity.
When their data were excluded, there was no significant
difference in fluid application between the HES group and
the gelatin group (SMD= −0.12, 95% CI −0.37 to 0.13;
P = 0.35; I2 = 0%) (Figure 7B).
Length of ICU and hospital stay
Eleven articles reported the length of ICU stay, and nine
articles reported the length of hospital stay. However,
significant heterogeneity was detected in both (ICU stay:Figure 6 Forest plots of pooled estimates for bleeding volume and re
blood cell transfusion (unit). HES, hydroxethyl starch. IV, Inverse Variance.I2 = 85%; hospital stay: I2 = 78%). As the heterogeneity
could not be excluded through subgroup analysis or
sensitivity analysis, a description was provided instead of
performing a meta-analysis. These data are not shown.
Discussion
The main finding of this meta-analysis showed that HES
was not associated with decreased overall mortality and
RRT use. These findings were similar with subgroup
analyses of non-septic patients among critically ill patients
or among all patients [8,9]. Our results were somewhat
different from a previous meta-analysis of fluid therapy in
critically ill patients, especially septic patients [43]. One
major cause was that the existing data for these patients
treated with HES was poor and scarce, which meant thed blood cell transfusion. (A) Bleeding volume after surgery. (B) Red
Figure 7 Forest plots of pooled estimates for fluid application (mL) during the first day in the ICU. (A) Hydroxethyl starch (HES) versus
crystalloid. (B) HES versus gelatin. (C) HES versus albumin. IV, Inverse Variance.
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quality. Another reason might also be that the patho-
physiological changes in these non-septic patients are
different from those in septic patients, and sepsis
itself could significantly increase the risk of AKI [44].
Micro leakage of capillary blood vessels was a key
pathophysiologic mechanism in sepsis [45], and endo-
thelial glycocalix plays an important role in micro
leakage of capillary blood vessels [46]. Steppan et al.
found that significantly more flaking of the endothelial
glycocalix occurred in patients with sepsis than in patients
who underwent major abdominal surgery [47]. In addition,
sepsis could activate the renin-angiotensin-aldosterone
system (RAAS) in renal sympathetic and angiotensin
activities, which leads to vasoconstriction in patients
with sodium and water retention. As a result, septic
patients are predisposed to acute renal failure [44].
Hence, the side effects of HES might be more serious for
septic patients than non-septic patients in the ICU.
Although several studies tried to analyze the effect of
HES in a non-septic subgroup, the results of their
subgroup analyses were always different from their
main results [8,9]. In addition, their analyses were always
part of the side effects of HES. Hence, we have made a
meta-analysis to study the effect HES versus other fluids
for non-septic ICU patients, including mortality, RRT use,
bleeding volume, RBC transfusion and fluid application.
This analysis was relatively comprehensive and with less
heterogenicity in non-septic patients. Furthermore, it
reminded us to pay more attention to volume expansion
therapy in ICU non-septic patients.The pooled analysis of overall mortality did not display
more harm with HES, which was not entirely the same
as previous trials [5-7] and meta-analyses [8,10,48,49].
Knowing that the pooled analysis of mortality may be
influenced by study quality and the follow-up period,
it is difficult to explain this result. On the one hand,
HES may have different effects in different diseases
[5-7,13,14]. On the other hand, study quality and the
follow-up period may induce bias in our meta-analysis, as
most included RCTs were small-sample studies and with
short follow-up periods. Hence, we should be cautious
when selecting fluids for ICU non-septic patients. In
addition, the article from CHEST [6] alone accounted for
88.9% of the weighting, and the results, which played an
important role in our meta-analysis, might only be suitable
for the specific clinical conditions in that study (for
example, a small dose of HES was chosen). We have
performed a sensitivity analysis, and its exclusion did not
influence the significance of the effect on overall mortality
(RR = 0.83, 95% CI 0.56 to 1.24; P = 0.37; I2 = 0). However,
other included studies were all with very small-scale
samples; more high-quality RCTs focusing on 6% HES in
non-septic ICU patients are needed to confirm our results.
Efforts were also made to determine the effect of
6% HES on renal function. However different indica-
tors were used to test renal function, such as blood
creatinine [32], glomerular filtration rate [30], the
incidence of AKI based on different criteria [24,34,42]
and RRT use [24-27,31,34,37,41,42]. The result need
further confirmation because of the limitations of our
included RCTs.
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and RBC transfusion between the 6% HES group and the
other fluid groups. Patients in the HES group received fewer
total intravenous fluids than those receiving crystalloids
during the first day in ICU, which might mean that 6% HES
had a better volume-expansion effect than crystalloids.
However, due to the absence of demonstrable benefit, more
large-scale RCTs are needed to confirm these results.
The implementation of our meta-analysis is in accordance
with the requirements of the Cochrane Collaboration.
These requirements include a literature search without
language limitations, strict inclusion and exclusion criteria,
selection of articles and collection of data by two independ-
ent authors, and bias risk evaluation. Indeed, there are
several limitations in our meta-analysis. Despite widespread
use of HES for more than three decades, RCTs comparing
HES with other fluids for ICU non-septic patients are few,
with small sample sizes, and vulnerable to bias. In addition,
several control groups in the included studies used gelatin,
which clouds or conceals the adverse effects of HES to
some extent. Bleeding volume analysis is limited by clinical
heterogeneity across studies because patients have under-
gone different types of surgery.Conclusion
Although volume expansion with 6% HES did not seem
to increase the mortality or RRT use in non-septic ICU
patients, the sample sizes in our meta-analysis were
small and the studies generally were of poor quality.Key messages
 The safety of HES for non-septic patients in the
ICU remains elusive
 Available data from systematic reviews and
meta-analyses displayed inconsistent results
between septic and non-septic patients using HES
 Use of 6% HES did not seem to increase the
mortality or RRT incidence in non-septic ICU
patientsAdditional files
Additional file 1: A priori design, electronic search strategy and
studies excluded from this review.
Additional file 2: Table S1. Observation period for outcomes.Abbreviations
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